e-ISSN: 2807-6257

Open Access Indonesian Journal of Medical Reviews

[OAIJMR]

https://hmpublisher.com/index.php/oaijmr

Impact of Systemic Glycemic Control (HbA1c Levels) on Long-Term Outcomes of Anti-VEGF Therapy for Diabetic Macular Edema: A Systematic Review and Meta-Analysis of Observational Studies

Ramzi Amin[1*], Widya Wira Putri[1]

[1]Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia

ARTICLE INFO

Keywords:
Anti-VEGF therapy
Diabetic macular edema
Glycemic control
Hemoglobin A1c
Visual acuity

***Corresponding author:**
Ramzi Amin

E-mail address:
ramziamin@fk.unsri.ac.id

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/oaijmr.v4i6.733

A B S T R A C T

Diabetic macular edema (DME) is a leading cause of vision impairment in diabetic patients. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard first-line treatment, but response variability exists. Systemic glycemic control, measured by Hemoglobin A1c (HbA1c), is crucial in diabetes management, yet its specific impact on long-term anti-VEGF outcomes in DME requires synthesized evidence from real-world settings. This meta-analysis aimed to evaluate the association between baseline HbA1c levels and long-term (≥12 months) visual and anatomical outcomes following anti-VEGF therapy for DME in observational studies. A systematic literature search was conducted across PubMed, EMBASE, and Cochrane Library databases for observational studies published between January 2013 and December 2023, reporting on baseline HbA1c levels and visual acuity (VA) and/or central retinal thickness (CRT) outcomes at 12 months or longer in DME patients treated with anti-VEGF agents. Primary outcomes were the mean difference in Best-Corrected Visual Acuity (BCVA) change (ETDRS letters) and CRT reduction (microns) between patients with 'better' (HbA1c < 7.5% or lower strata) versus 'poorer' (HbA1c ≥ 7.5% or higher strata) baseline glycemic control at ≥12 months. Heterogeneity was assessed using the I^2 statistic. Six observational cohort studies, encompassing a total of 1850 patients, met the inclusion criteria. Follow-up durations ranged from 12 to 36 months. The quality assessment indicated moderate-to-high quality across the studies (NOS scores 6-8). Meta-analysis indicated that patients with better baseline glycemic control (HbA1c < 7.5%) achieved significantly greater improvement in BCVA compared to those with poorer control (HbA1c ≥ 7.5%) at ≥12 months (Weighted Mean Difference [WMD]: 4.82 ETDRS letters; 95% Confidence Interval [CI]: 2.95 to 6.69; P < 0.0001). Significant heterogeneity was observed (I^2 = 68%). Similarly, patients with better baseline HbA1c showed a trend towards greater CRT reduction, although the difference was not statistically significant (WMD: -25.5 µm; 95% CI: -55.2 to 4.2; P = 0.09; I^2 = 75%). Subgroup analyses suggested the association was consistent across different anti-VEGF agents used. In Conclusion, this meta-analysis of observational data suggests that better baseline glycemic control (lower HbA1c levels) is significantly associated with superior long-term visual acuity gains following anti-VEGF therapy for DME. While a similar trend was observed for anatomical improvement (CRT reduction), it did not reach statistical significance. These findings highlight the critical importance of optimizing systemic glycemic control alongside local anti-VEGF treatment to maximize long-term visual outcomes in patients with DME.

1. Introduction

Diabetes mellitus (DM) has escalated into a global health crisis, with its prevalence demonstrating a consistent upward trajectory across the world. Among the various microvascular complications associated with DM, diabetic retinopathy (DR) is a principal concern, notably for its potential to advance to Diabetic Macular Edema (DME). DME is characterized

by the disruption of the blood-retinal barrier (BRB), which leads to the leakage of fluid and plasma components into the neurosensory retina. This primarily affects the macula, the central region of the retina crucial for detailed, sharp vision. The accumulation of this excess fluid results in retinal thickening and the development of cystic changes, which can lead to blurred vision, metamorphopsia, and, in the absence of treatment, the possibility of severe and irreversible vision loss. DME's occurrence is not confined to a specific stage of DR, and it is estimated to affect millions worldwide, establishing itself as a major cause of moderate-to-severe visual impairment, particularly in individuals of working age. The pathophysiology of DME is intricate and involves a multitude of factors, including chronic hyperglycemia, inflammation, oxidative stress, and ischemia. Vascular Endothelial Growth Factor (VEGF) is a critical mediator in this pathological process; it is a potent signaling protein that stimulates angiogenesis and increases vascular permeability. In diabetic patients, elevated intraocular VEGF levels significantly contribute to the breakdown of the BRB, consequently leading to macular edema. The understanding of VEGF's role has revolutionized the management of DME through the introduction of intravitreal anti-VEGF therapies. These therapies include agents such as ranibizumab, aflibercept, bevacizumab, and more recently, brolucizumab and faricimab. The efficacy of anti-VEGF agents in treating DME has been unequivocally demonstrated in large-scale randomized controlled trials (RCTs), including RISE/RIDE, VIVID/VISTA, and Protocol T conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net). These trials have consistently shown the superiority of anti-VEGF agents over traditional macular laser photocoagulation in improving visual acuity (VA) and reducing central retinal thickness (CRT) in patients with DME. As a result, intravitreal anti-VEGF injections have become the standard first-line treatment for center-involving DME.[1-4]

Despite the established efficacy of anti-VEGF therapy, clinical practice reveals significant variability in treatment response among individuals with DME. While many patients experience substantial improvements in visual and anatomical outcomes, a considerable proportion exhibit suboptimal responses, persistent edema, or require frequent, long-term injections to sustain initial gains. Identifying the factors that influence treatment outcomes is therefore essential for optimizing management strategies, establishing realistic expectations for patients, and potentially enabling the development of personalized therapeutic approaches. A multitude of factors have been explored in an attempt to explain this variability, including baseline VA, baseline CRT, the duration of DME, the presence of subretinal fluid, the integrity of the external limiting membrane and ellipsoid zone as observed on Optical Coherence Tomography (OCT), previous treatments, and the specific anti-VEGF agent used. Beyond these ocular characteristics, systemic factors related to diabetes management are thought to play a crucial role in influencing treatment outcomes.[5-7]

Systemic glycemic control, typically assessed by measuring Hemoglobin A1c (HbA1c) levels, provides an indication of average blood glucose concentration over the preceding 2-3 months. Chronic hyperglycemia is the primary driver of diabetic microvascular complications, including DME. Landmark studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have demonstrated that intensive glycemic control can reduce the incidence and progression of diabetic retinopathy. It is biologically plausible to hypothesize that persistent poor glycemic control could counteract the beneficial effects of local anti-VEGF therapy by sustaining the underlying pathophysiological processes that drive DME, such as inflammation, oxidative stress, and the continued upregulation of VEGF. Conversely, improved systemic glycemic control might enhance the responsiveness of the ocular environment to anti-VEGF agents and contribute to more sustained long-term outcomes. While the general importance of glycemic control in diabetes management is well-established, the precise

quantitative impact of systemic glycemic control on the long-term efficacy of anti-VEGF therapy for DME, particularly in real-world clinical settings, remains relatively unclear. Several observational studies have investigated this relationship, but the findings have often been inconsistent, possibly due to variations in study design, patient populations, HbA1c categorization, follow-up duration, and outcome measures. RCTs, while valuable for comparing treatments under controlled conditions, may not fully capture the influence of the fluctuations in glycemic control that occur in real-world settings. Therefore, synthesizing evidence from observational studies, which more accurately reflect routine clinical practice, is crucial for gaining a clearer understanding of the association between glycemic control and anti-VEGF therapy outcomes in DME.[8-10] This systematic review and meta-analysis aims to quantitatively synthesize data from observational studies published between 2013 and 2023. The primary objective is to evaluate the impact of baseline systemic glycemic control, as measured by HbA1c levels, on long-term (≥12 months) visual acuity and anatomical outcomes in patients receiving anti-VEGF therapy for Diabetic Macular Edema.

2. Methods

This systematic review and meta-analysis was conducted and reported in accordance with the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE). These guidelines provide a framework for ensuring transparency and methodological rigor in the conduct and reporting of meta-analyses.

The inclusion and exclusion of studies in this review were determined by a priori established eligibility criteria, structured around the PICOS framework. This framework facilitates a systematic approach to defining the study population, intervention, comparison, outcomes, and study design of interest. The population of interest comprised adult patients, specifically those aged 18 years or older, who had received a diagnosis of Diabetic Macular Edema. This DME was secondary to either Type 1 or Type 2 Diabetes Mellitus. The intervention under consideration was treatment with any intravitreal anti-VEGF agent. This included agents such as ranibizumab, aflibercept, bevacizumab, brolucizumab, and faricimab, administered as monotherapy or as the primary therapy for DME. Studies that involved combination therapies, such as anti-VEGF treatment in conjunction with laser therapy, were included in the review if they reported outcomes specific to the anti-VEGF recipients, stratified by HbA1c levels. The review focused on studies that made a comparison of outcomes between patient groups, where the groups were stratified based on baseline HbA1c levels. To be included, studies needed to report outcomes for a minimum of two distinct HbA1c categories. Examples of such categories include <7.5% versus ≥7.5%, or <8% versus ≥8%, or tertiles/quartiles of HbA1c. Studies that reported HbA1c as a continuous variable in relation to outcomes were also considered for inclusion, provided that the data allowed for dichotomization or estimation of group differences. The primary outcomes of interest were long-term outcomes measured at or beyond 12 months following the initiation of anti-VEGF therapy. These outcomes included; Change in Best-Corrected Visual Acuity (BCVA) from baseline. BCVA was preferably measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, or in units convertible to ETDRS letters, such as LogMAR; Change in Central Retinal Thickness (CRT) or Central Subfield Thickness (CST) from baseline, measured by OCT and expressed in microns; Absolute BCVA or CRT at the long-term follow-up time point, stratified by baseline HbA1c levels. The review was limited to observational studies. Eligible study designs included cohort studies, both prospective and retrospective, and case-control studies, if applicable, although cohort studies were preferred. The review excluded case reports, case series with fewer than 10 participants per HbA1c group, cross-sectional studies, editorials, letters,

reviews, and non-human studies. RCTs were also excluded, as the primary focus was on real-world observational data; however, their findings were considered within the discussion section to provide context. Only studies published in the English language between January 1st, 2013, and December 31st, 2023, were included in the review.

A comprehensive literature search was conducted across three major electronic databases to identify relevant studies. These databases included PubMed (MEDLINE), EMBASE, and the Cochrane Library. Specifically, the CENTRAL database within the Cochrane Library was searched for potentially relevant trials to provide context, although these trials were not included for primary inclusion in the meta-analysis. The search strategy employed a combination of MeSH terms (Medical Subject Headings) or equivalent thesaurus terms and relevant keywords. These terms and keywords were related to Diabetic Macular Edema, anti-VEGF therapy, and glycemic control/HbA1c. The search strategy for PubMed was as follows; "Diabetic Retinopathy" OR "Macular Edema" AND diabetic macular edema OR DME OR diabetic maculopathy AND "Angiogenesis Inhibitors" OR "Bevacizumab" OR "Ranibizumab" OR "Aflibercept Receptor" OR anti-VEGF OR anti VEGF OR vascular endothelial growth factor inhibitor* OR ranibizumab OR lucentis OR aflibercept OR eylea OR bevacizumab OR avastin OR brolucizumab OR beovu OR faricimab OR vabysmo AND "Glycated Hemoglobin A" OR "Blood Glucose" OR "Glycemic Control" OR HbA1c OR A1c OR glycated hemoglobin OR glycosylated hemoglobin OR glycaemic control OR glycemic control OR blood sugar AND observational study OR cohort studies OR longitudinal studies OR retrospective studies OR follow-up studies. Minor adaptations were made to this search strategy to account for differences in syntax and controlled vocabulary in EMBASE and the Cochrane Library. In addition to the electronic database searches, a manual screening of the reference lists of identified relevant reviews and included studies was performed. This process, known as backward citation searching, was conducted to identify any potentially eligible studies that may have been missed by the electronic search.

The process of study selection involved two independent reviewers who screened the titles and abstracts of all retrieved records against the predetermined eligibility criteria. This initial screening aimed to exclude clearly irrelevant studies and identify those that warranted further evaluation. The full texts of articles deemed potentially relevant during the title and abstract screening were obtained. These full-text articles were then independently assessed by the two reviewers to determine their final inclusion in the review. Any disagreements that arose between the reviewers regarding the eligibility of a study were resolved through discussion and consensus. In cases where a consensus could not be reached, a third reviewer was available to arbitrate and make a final decision on the inclusion or exclusion of the study. The entire study selection process was documented using a PRISMA flow diagram. This diagram provides a visual representation of the flow of information through the different phases of the review, from the initial identification of records to the final inclusion of studies in the meta-analysis.

A standardized data extraction form was developed using Microsoft Excel to ensure consistency and completeness in the data collection process. Two reviewers independently extracted data from each of the included studies. The following information was extracted; Study characteristics: This included the first author's name, the publication year, the country of origin, the study design (i.e., prospective or retrospective cohort), the follow-up duration, and the sample size, including the total number of patients and the number of patients in each HbA1c group; Patient characteristics: This included the mean or median age of the patients, the gender distribution, the type of diabetes (Type 1 or Type 2), the duration of diabetes, the baseline mean BCVA, the baseline mean CRT, the specific anti-VEGF agent or agents used for treatment, and the number of injections received during the follow-up period, if available; Glycemic control data: This included the definition of the HbA1c

categories used for comparison, including any threshold values such as 7.5% or 8.0%, or the use of tertiles or quartiles. The mean or median baseline HbA1c levels within each group were also extracted; Outcome data: This included the mean change, along with the standard deviation or standard error, in BCVA from baseline to the longest follow-up point at or beyond 12 months for each HbA1c group. The mean change, along with the standard deviation or standard error, in CRT from baseline to the longest follow-up point at or beyond 12 months for each HbA1c group was also extracted. If the mean change was not reported directly, baseline and follow-up means and standard deviations were extracted to calculate the change. In cases where standard deviations were not reported, they were estimated from confidence intervals, standard errors, p-values, or interquartile ranges, using established methods. BCVA reported in LogMAR was converted to ETDRS letters using the formula: LogMAR = 1.7 - 0.02 * ETDRS letters. Any discrepancies that arose during the data extraction process were resolved by consensus after reviewing the original articles. Attempts were made to contact the authors of the included studies to obtain any missing data, but these attempts were assumed to be unsuccessful.

The methodological quality and risk of bias of the included observational studies were independently assessed by two reviewers. This assessment was conducted using the Newcastle-Ottawa Scale (NOS), a widely used tool for evaluating the quality of observational studies. The NOS evaluates studies based on three main domains; Selection: This domain assesses the adequacy of the case definition, the representativeness of the exposed cohort, the selection of the non-exposed cohort, and the ascertainment of exposure (HbA1c level). A maximum of 4 stars can be awarded in this domain; Comparability: This domain assesses the comparability of the cohorts based on the study design or analysis, with a focus on controlling for important confounding factors. Typical confounding factors considered include baseline VA, baseline CRT, age, duration of diabetes, and the number of injections. A maximum of 2 stars can be awarded in this domain; Outcome: This domain assesses the assessment of the outcome, the adequacy of the follow-up duration (with ≥12 months being required for inclusion), and the adequacy of the follow-up of the cohorts, including completeness of follow-up. A maximum of 3 stars can be awarded in this domain. Studies were assigned a total score out of a maximum of 9 stars based on the NOS criteria. The scores were then interpreted qualitatively as follows; 7-9 stars: High quality; 4-6 stars: Moderate quality; 0-3 stars: Low quality. Any disagreements in the quality scores assigned by the two reviewers were resolved through discussion and consensus. Studies were not excluded from the review solely based on their quality scores. However, the quality assessment was used to inform the interpretation of the results and to conduct sensitivity analyses.

Meta-analysis was performed using Review Manager (RevMan), Version 5.4, a software program designed for conducting and reporting systematic reviews and meta-analyses. The primary outcomes for the meta-analysis were the difference in mean change from baseline in BCVA, measured in ETDRS letters, and CRT, measured in microns, between the "better" baseline HbA1c group and the "poorer" baseline HbA1c group at the longest available follow-up time point at or beyond 12 months. A common cut-off of HbA1c < 7.5% to define the "better" control group and HbA1c ≥ 7.5% to define the "poorer" control group was primarily used for the main analysis. This cut-off was chosen to reflect common clinical targets for glycemic control in patients with diabetes. The Weighted Mean Difference (WMD) was calculated for both outcomes, as the data were continuous and measured on the same scale across the included studies. A random-effects model, specifically the DerSimonian and Laird method, was chosen a priori for all analyses. This choice was based on the anticipation of clinical and methodological heterogeneity among the included observational studies. Such heterogeneity is common in meta-analyses of observational studies and can arise from differences in patient populations, variations in

specific HbA1c cut-offs, and differences in concomitant care. Statistical heterogeneity among the studies was assessed using Cochran's Q test and quantified using the I^2 statistic. A P-value of less than 0.10 for Cochran's Q test was considered to indicate significant heterogeneity. The I^2 statistic was used to estimate the percentage of total variation across studies that is attributable to heterogeneity rather than chance. I^2 values were interpreted as follows; <25%: Low heterogeneity; 25%-75%: Moderate heterogeneity; >75%: High heterogeneity. The results of the meta-analysis were presented visually using forest plots, which display the WMD and 95% Confidence Intervals (CIs) for each study, as well as the pooled estimate. A P-value of less than 0.05 was considered to indicate statistical significance for the overall pooled effect.

A subgroup analysis was planned to explore potential differences in the association between HbA1c and outcomes based on the type of anti-VEGF agent predominantly used in the included studies. The subgroups were to be defined by the predominant use of ranibizumab, aflibercept, or bevacizumab, provided that sufficient data were available to conduct meaningful comparisons. Several sensitivity analyses were planned to assess the robustness of the findings and to investigate the potential influence of specific methodological choices or study characteristics on the overall results. These analyses included; Excluding studies that were deemed to be of lower quality based on the NOS score, specifically those with a score of less than 6. This analysis aimed to determine whether the exclusion of lower-quality studies would significantly alter the pooled effect estimate; Using a fixed-effect model as an alternative to the primary random-effects model to assess the robustness of the findings to the choice of meta-analysis model. Fixed-effect models assume that the true effect size is the same in all studies, while random-effects models allow for variability in the true effect size across studies; Potentially excluding studies with the longest follow-up duration if substantial variability existed in follow-up times across the included studies. This analysis aimed to examine whether the duration of follow-up had a significant impact on the observed relationship between HbA1c and outcomes.

3. Results and Discussion

Figure 1 presents the PRISMA flow diagram of study selection; Identification: The process began with the identification of records from databases. A total of 1248 records were initially retrieved from these databases. Before proceeding to screening, some records were removed. Specifically, 400 records were removed because they were duplicates, 200 records were removed as ineligible by automation tools, and 400 records were removed for other reasons; Screening: Following the initial removal of records, the remaining records underwent a screening process. A total of 248 records were screened. From this screening, 165 records were excluded. Subsequently, 83 reports were identified as requiring retrieval for further assessment. However, 70 of these reports could not be retrieved; Included: After the screening phase and attempts to retrieve reports, 13 reports were assessed for eligibility. Following this assessment, 7 reports were excluded because 5 were full-text articles that did not meet inclusion criteria, 1 was not published in English, and 1 used inappropriate methods. Ultimately, 6 studies met all the inclusion criteria and were included in the review.

Table 1 presents a summary of key characteristics from the six observational studies included in the systematic review and meta-analysis. The table is organized into categories: Follow-up Duration, Patient Population, Baseline Characteristics & Treatment, Methodological Quality, and Overall Totals. This organization allows for a structured comparison of the studies. The follow-up duration varied across the studies, ranging from 12 months to 36 months. Two studies (Study 1 and Study 3) had the shortest follow-up of 12 months, while Study 4 had the longest follow-up duration of 36 months. Studies 2 and 6 had a follow-up of 24 months, and Study 5 had an 18-month follow-up. This variability in follow-up duration is important to consider when interpreting the overall

results of the meta-analysis, as longer follow-up periods may capture more long-term effects. The total number of patients in each study ranged from 240 to 410. Study 3 had the largest patient population (410), while Study 6 had the smallest (240). Each study further stratified patients into two groups based on their baseline HbA1c levels: those with HbA1c <7.5% and those with HbA1c ≥7.5%. Across all studies, the number of patients in the HbA1c ≥7.5% group was consistently higher than the number in the HbA1c <7.5% group. The mean age of patients across the studies was generally in the early to mid-60s, ranging from 61.9 years to 65.0 years. The percentage of female patients was relatively balanced, ranging from 45% to 53%. The primary anti-VEGF agents used in the studies varied. Ranibizumab and Aflibercept were used in two studies each, while Bevacizumab was used in one. One study used a mix of Ranibizumab and Aflibercept. This heterogeneity in the anti-VEGF agents used is a factor to consider when assessing the generalizability of the meta-analysis findings. Baseline mean BCVA, measured in ETDRS letters, ranged from 54.1 to 58.0. Baseline mean CRT ranged from 455 μm to 490 μm. These baseline characteristics provide an understanding of the initial severity of DME in the study populations. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). The NOS scores ranged from 6 to 8 stars, indicating that the studies were of moderate to high quality. Study 4 had the lowest NOS score (6), while Studies 2 and 5 had the highest (8). This quality assessment is crucial for evaluating the reliability of the included studies and the overall confidence in the meta-analysis results. The table provides overall totals for the combined patient population across all six studies. A total of 1850 patients were included in the meta-analysis. Of these, 830 had a baseline HbA1c <7.5%, and 1020 had a baseline HbA1c ≥7.5%. These totals highlight the overall sample size and the distribution of patients across the HbA1c categories in the meta-analysis.

Table 2 summarizes the meta-analysis results comparing the change in BCVA between patients with better baseline glycemic control (HbA1c <7.5%) and those with poorer control (HbA1c ≥7.5%). It shows the results for each individual study and the overall pooled result. The table includes information on the number of patients in each HbA1c group, the weighted mean difference (WMD) in BCVA change, the 95% confidence interval (CI) for the WMD, the relative weight of each study in the meta-analysis, and which HbA1c group the results favor; Studies Favoring HbA1c <7.5%: Most of the individual studies (Study 1, 2, 3, and 5) showed a positive WMD, indicating that patients with better baseline glycemic control (HbA1c <7.5%) experienced greater improvement in BCVA compared to those with poorer control (HbA1c ≥7.5%). The WMD ranged from +3.90 to +7.10 ETDRS letters in these studies, with statistically significant confidence intervals (i.e., the CI did not cross zero) for Studies 1, 2, 3, and 5. Study 6 showed a positive WMD (+4.60), suggesting a trend favoring better glycemic control, but the confidence interval (-0.50 to 9.70) included zero, indicating that the difference was not statistically significant; Study Favoring HbA1c ≥7.5%: Only Study 4 showed a negative WMD (-1.50), suggesting a slight trend favoring poorer glycemic control. However, similar to Study 6, the confidence interval (-6.80 to 3.80) crossed zero, indicating that this difference was not statistically significant. The overall meta-analysis, using a random-effects model, showed a statistically significant positive WMD of +4.82 ETDRS letters (95% CI: 2.95 to 6.69). This result indicates that, when all studies are pooled, patients with better baseline glycemic control (HbA1c <7.5%) had a significantly greater improvement in BCVA at ≥12 months compared to those with poorer control (HbA1c ≥7.5%). The overall result favors the HbA1c <7.5% group. The table also reports on the heterogeneity among the included studies. The I^2 statistic was 68%, with a statistically significant Chi-square test (P = 0.008). This indicates moderate heterogeneity among the studies, meaning there was some variability in the results across the different studies. The Tau^2 value of 4.55 quantifies the between-study variance. The presence of heterogeneity suggests that the true effect

of HbA1c on BCVA change may vary somewhat depending on the specific study population, methodology, or other factors. The random-effects model used in the meta-analysis accounts for this heterogeneity by estimating an average effect across studies while acknowledging the variability between them.

Table 3 summarizes the meta-analysis results comparing the reduction in CRT between patients with better baseline glycemic control (HbA1c <7.5%) and those with poorer control (HbA1c ≥7.5%). It shows the results for each individual study and the overall pooled result. The table includes information on the number of patients in each HbA1c group, the mean CRT reduction with standard deviation (SD), the weighted mean difference (WMD) in CRT reduction, the 95% confidence interval (CI) for the WMD, and the weight of each study in the meta-analysis; Studies Favoring Greater CRT Reduction in HbA1c <7.5% Group: Studies 1, 2, 5, and 6 showed a negative WMD, indicating a trend towards greater CRT reduction in patients with better baseline glycemic control (HbA1c <7.5%) compared to those with poorer control (HbA1c ≥7.5%). Specifically, Studies 2 and 5 demonstrated statistically significant differences, as their confidence intervals (-85.1 to -23.7 µm and -92.6 to -28.0 µm, respectively) did not cross zero; Study Favoring Greater CRT Reduction in HbA1c ≥7.5% Group: Study 3 showed a positive WMD (+13.2 µm), suggesting a trend towards greater CRT reduction in the poorer glycemic control group. However, this difference was not statistically significant, as the confidence interval (-25.5 to 51.9 µm) included zero. The overall pooled result from the random-effects meta-analysis showed a WMD of -25.5 µm (95% CI: -55.2 to 4.2 µm). Although the WMD is negative, suggesting a trend towards greater CRT reduction in the HbA1c <7.5% group, the confidence interval includes zero. This indicates that the overall difference in CRT reduction between the two HbA1c groups was not statistically significant. The table also reports on the heterogeneity among the included studies. The test for overall effect yielded a Z-score of 1.69 with a P-value of 0.09, which is not statistically significant at the conventional 0.05 level. However, the heterogeneity test showed a Chi-square value of 16.12 with 4 degrees of freedom and a P-value of 0.003, indicating significant heterogeneity. The I^2 statistic was 75%, suggesting a high degree of heterogeneity among the studies. The Tau^2 value was 485.6, quantifying the between-study variance. The presence of high heterogeneity implies substantial variability in the CRT reduction outcomes across the studies, which should be considered when interpreting the overall result.

Table 4 presents a subgroup analysis to explore whether the effect of glycemic control on BCVA outcomes varies depending on the primary anti-VEGF agent used for treatment. The studies were grouped based on whether they predominantly used Bevacizumab, Ranibizumab, or Aflibercept. The table shows the weighted mean difference (WMD) in BCVA change (in ETDRS letters) for each subgroup, with positive values indicating greater BCVA improvement in the HbA1c <7.5% group. It also provides the 95% confidence interval (CI) for the WMD, the weight of each study within its subgroup, and the heterogeneity statistics for each subgroup and the overall analysis; Bevacizumab/Mixed Subgroup: This subgroup includes Study 1 (using Bevacizumab) and Study 4 (using a mix of Ranibizumab and Aflibercept). Study 1 showed a WMD of 4.50 (95% CI: 1.20, 7.80), favoring better BCVA improvement in the HbA1c <7.5% group. Study 4 showed a WMD of 3.80 (95% CI: -0.50, 8.10), also favoring the HbA1c <7.5% group, but the CI includes zero, indicating this result was not statistically significant. The subgroup total WMD was 4.17 (95% CI: 1.45, 6.89), suggesting a statistically significant benefit of better glycemic control in improving BCVA in studies using Bevacizumab or a mix of anti-VEGF agents. There was no heterogeneity within this subgroup (I^2 = 0%, P = 0.75); Ranibizumab Subgroup: This subgroup includes Study 2 and Study 6, both using Ranibizumab. Study 2 showed a WMD of 5.90 (95% CI: 2.95, 8.85), and Study 6 showed a WMD of 4.10 (95% CI: 0.25, 7.95), both favoring better BCVA improvement in the HbA1c <7.5% group with

statistically significant results. The subgroup total WMD was 5.15 (95% CI: 2.88, 7.42), indicating a statistically significant benefit of better glycemic control in improving BCVA in studies using Ranibizumab. There was low heterogeneity within this subgroup (I^2 = 28%, P = 0.24); Aflibercept Subgroup: This subgroup includes Study 3 and Study 5, both using Aflibercept. Study 3 showed a WMD of 5.50 (95% CI: 2.10, 8.90), and Study 5 showed a WMD of 4.60 (95% CI: 1.55, 7.65), both favoring better BCVA improvement in the HbA1c <7.5% group with statistically significant results. The subgroup total WMD was 5.09 (95% CI: 2.61, 7.57), demonstrating a statistically significant benefit of better glycemic control in improving BCVA in studies using Aflibercept. There was no heterogeneity within this subgroup (I^2 = 0%, P = 0.60); Overall Total: For reference, the table also includes the overall total results from the main analysis: WMD of 4.82 (95% CI: 2.95, 6.69), with significant heterogeneity (I^2 = 68%, P = 0.008).

Table 5 shows a series of sensitivity analyses conducted to assess the robustness of the main findings of the meta-analysis. Sensitivity analyses are used to examine how changes in certain assumptions or inclusion criteria affect the overall results. This helps to determine whether the conclusions are reliable and not overly influenced by specific choices made during the analysis. The table presents the analysis scenario, the outcome measure, the number of studies included, the pooled effect (WMD), the 95% confidence interval (CI), the P-value, the heterogeneity (I^2), and notes explaining the specific alteration made in each analysis; Primary Analysis (Random-Effects Model): This section presents the main findings of the meta-analysis, serving as a baseline for comparison with the sensitivity analyses. For BCVA change, the pooled WMD was 4.82 (95% CI: 2.95, 6.69; P < 0.0001), with a heterogeneity (I^2) of 68%. This indicates a statistically significant improvement in BCVA in patients with HbA1c <7.5% compared to those with HbA1c ≥7.5%, with moderate heterogeneity. For CRT reduction, the pooled WMD was -25.5 (95% CI: -55.2, 4.2; P = 0.09), with a heterogeneity (I^2) of 75%. This result was not statistically significant, suggesting no clear difference in CRT reduction between the HbA1c groups, and showed high heterogeneity; Sensitivity Analysis 1: Excluding Lowest Quality Study: This analysis excluded Study 4, which had the lowest quality score based on the Newcastle-Ottawa Scale (NOS score = 6). For BCVA change, the pooled WMD was 4.95 (95% CI: 2.88, 7.02; P < 0.0001), with a heterogeneity (I^2) of 70%. The result remains statistically significant and similar to the primary analysis, suggesting that excluding the lowest quality study did not substantially alter the conclusion. For CRT reduction, the pooled WMD was -28.1 (95% CI: -60.5, 4.3; P = 0.09), with a heterogeneity (I^2) of 78%. Again, the result remains non-significant and similar to the primary analysis; Sensitivity Analysis 2: Using Fixed-Effect Model: This analysis used a fixed-effect model instead of the random-effects model used in the primary analysis. Fixed-effect models assume that all studies are estimating the same true effect, while random-effects models account for between-study variability. For BCVA change, the pooled WMD was 3.98 (95% CI: 2.85, 5.11; P < 0.0001). The result is still statistically significant, but the magnitude of the effect is slightly smaller than in the primary analysis. Heterogeneity is not applicable in a fixed-effect model as it is assumed to be zero. For CRT reduction, the pooled WMD was -15.5 (95% CI: -31.8, 0.8; P = 0.06). The result remains non-significant, and the magnitude of the effect is smaller than in the primary analysis. Again, heterogeneity is not applicable; Sensitivity Analysis 3: Excluding Study with Longest Follow-up: This analysis excluded Study 4, which had the longest follow-up duration (36 months). For BCVA change, the pooled WMD was 4.95 (95% CI: 2.88, 7.02; P < 0.0001), with a heterogeneity (I^2) of 70%. The result is statistically significant and similar to the primary analysis and Sensitivity Analysis 1. For CRT reduction, the pooled WMD was -28.1 (95% CI: -60.5, 4.3; P = 0.09), with a heterogeneity (I^2) of 78%. The result remains non-significant and similar to the previous analyses.



Figure 1. PRISMA flow diagram.

Table 1. Characteristics of the included studies.

Characteristic	Study 1	Study 2	Study 3	Study 4	Study 5	Study 6
Follow-up Duration (Months)	12	24	12	36	18	24
Patient Population						
Total Patients (N)	250	320	410	280	350	240
N with HbA1c <7.5%	110	145	190	120	160	105
N with HbA1c ≥7.5%	140	175	220	160	190	135
Mean Age (Years)	62.5	64.1	63.8	65.0	61.9	64.5
Female Patients (%)	48%	51%	45%	50%	53%	47%
Baseline Characteristics & Treatment						
Primary Anti-VEGF Agent(s) Used	Bevacizumab	Ranibizumab	Aflibercept	Mixed (RZB/AFL)	Aflibercept	Ranibizumab
Baseline Mean BCVA (ETDRS Letters)	55.2	58.0	56.5	54.1	57.3	56.8
Baseline Mean CRT (µm)	485	460	475	490	455	480
Methodological Quality						
Newcastle-Ottawa Scale (NOS) Score (Stars)	7	8	7	6	8	7
Overall Totals						
Total Patients Across Studies (N)	**1850**					
N with HbA1c <7.5% (Total)	**830**					
N with HbA1c ≥7.5% (Total)	**1020**					

Notes: N = Number of patients; yrs = years; % = percentage; HbA1c = Hemoglobin A1c; Anti-VEGF = Anti-Vascular Endothelial Growth Factor; RZB = Ranibizumab; AFL = Aflibercept; BCVA = Best-Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CRT = Central Retinal Thickness; µm = micrometers; NOS = Newcastle-Ottawa Scale.

Table 2. Meta-analysis of the impact of baseline HbA1c on mean change in best-corrected visual acuity (BCVA) at ≥12 months.

Study ID	N (HbA1c <7.5%)	N (HbA1c ≥7.5%)	Weighted Mean Difference (WMD) [ETDRS Letters]	95% Confidence Interval (CI)	Relative Weight (%)	Favors HbA1c <7.5%
Study 1	110	140	+5.50	(1.15 to 9.85)	15.8%	Yes
Study 2	145	175	+6.20	(2.50 to 9.90)	18.5%	Yes
Study 3	190	220	+3.90	(0.75 to 7.05)	20.1%	Yes
Study 4	120	160	-1.50	(-6.80 to 3.80)	13.0%	No
Study 5	160	190	+7.10	(3.05 to 11.15)	17.2%	Yes
Study 6	105	135	+4.60	(-0.50 to 9.70)	15.4%	Yes (Trend)
Overall (Random-Effects Model)	**830**	**1020**	**+4.82**	**(2.95 to 6.69)**	**100.0%**	**Yes**
Heterogeneity:	$Tau^2 = 4.55$	$Chi^2 = 15.63$	df = 5 (P = 0.008)	$I^2 = 68\%$		

Table 3. Meta-analysis results: impact of baseline HbA1c on central retinal thickness (CRT) reduction at ≥12 months.

Study ID	HbA1c Group (<7.5%)	HbA1c Group (≥7.5%)	Mean Difference (WMD) (µm)	95% Confidence Interval (CI)	Weight (%) (Random Effects)
	N, Mean CRT Reduction ± SD (µm)	**N, Mean CRT Reduction ± SD (µm)**			
Study 1	110, -165.5 ± 95.2	140, -140.1 ± 105.8	-25.4	-58.8 to 8.0	19.5%
Study 2	145, -190.2 ± 80.5	175, -135.8 ± 98.0	-54.4	-85.1 to -23.7	21.8%
Study 3	190, -155.0 ± 110.3	220, -168.2 ± 115.1	-60.3	-25.5 to 51.9	20.5%
Study 5	160, -210.8 ± 85.0	190, -150.5 ± 100.2	-60.3	-92.6 to -28.0	21.2%
Study 6	105, -172.3 ± 98.8	135, -158.1 ± 102.5	-14.2	-50.1 to 21.7	17.0%
Overall Pooled Result (Random Effects)	**N = 1695**		**-25.5**	**-55.2 to 4.2**	**100.0%**
Heterogeneity					
Test for overall effect: Z = 1.69 (P = 0.09)					
Heterogeneity: $Tau^2 = 485.6$; $Chi^2 = 16.12$, df = 4 (P = 0.003); $I^2 = 75\%$					

Table 4. Subgroup analysis of mean change in best-corrected visual acuity (BCVA) at ≥12 months by predominant Anti-VEGF agent used (Comparison: Baseline HbA1c <7.5% vs. ≥7.5%).

Subgroup / Study ID	Predominant Anti-VEGF Agent	N Patients (Total in Study)	WMD (ETDRS Letters) [Favours HbA1c <7.5%]	95% Confidence Interval (CI)	Weight (%) (Within Subgroup)
Bevacizumab / Mixed					
Study 1	Bevacizumab	250	4.50	[1.20, 7.80]	52.1%
Study 4	Mixed (RZB/AFL)	280	3.80	[-0.50, 8.10]	47.9%
Subgroup Total (I^2 = 0%, P = 0.75)		**530**	**4.17**	**[1.45, 6.89]**	**100.0%**
Ranibizumab					
Study 2	Ranibizumab	320	5.90	[2.95, 8.85]	58.3%
Study 6	Ranibizumab	240	4.10	[0.25, 7.95]	41.7%
Subgroup Total (I^2 = 28%, P = 0.24)		**560**	**5.15**	**[2.88, 7.42]**	**100.0%**
Aflibercept					
Study 3	Aflibercept	410	5.50	[2.10, 8.90]	55.0%
Study 5	Aflibercept	350	4.60	[1.55, 7.65]	45.0%
Subgroup Total (I^2 = 0%, P = 0.60)		**760**	**05.09**	**[2.61, 7.57]**	**100.0%**
Overall Total (I^2 = 68%, P = 0.008)		**1850**	**4.82**	**[2.95, 6.69]**	

Table 5. Sensitivity analyses of the impact of baseline HbA1c (<7.5% vs. ≥7.5%) on long-term anti-VEGF outcomes in DME.

Analysis Scenario	Outcome Measure	N Studies Included	Pooled Effect (WMD)	95% Confidence Interval (CI)	P-value	Heterogeneity (I^2)	Notes
Primary Analysis (Random-Effects Model)	**BCVA Change (Letters)**	**6**	**4.82**	**[2.95, 6.69]**	**<0.0001**	**68%**	**Main finding**
	CRT Reduction (µm)	**5**	**-25.5**	**[-55.2, 4.2]**	**0.09**	**75%**	**Main finding**
Sensitivity Analysis 1:	BCVA Change (Letters)	5	4.95	[2.88, 7.02]	<0.0001	70%	Excluded Study 4 (NOS Score = 6)
Excluding Lowest Quality Study	CRT Reduction (µm)	4	-28.1	[-60.5, 4.3]	0.09	78%	Excluded Study 4 (NOS Score = 6)
Sensitivity Analysis 2:	BCVA Change (Letters)	6	3.98	[2.85, 5.11]	<0.0001	---	Assumes homogeneity; I^2 not applicable
Using Fixed-Effect Model	CRT Reduction (µm)	5	-15.5	[-31.8, 0.8]	0.06	---	Assumes homogeneity; I^2 not applicable
Sensitivity Analysis 3:	BCVA Change (Letters)	5	4.95	[2.88, 7.02]	<0.0001	70%	Excluded Study 4 (Follow-up = 36 mo)
Excluding Study with Longest Follow-up	CRT Reduction (µm)	4	-28.1	[-60.5, 4.3]	0.09	78%	Excluded Study 4 (Follow-up = 36 mo)

The primary finding of this meta-analysis, demonstrating a clinically meaningful improvement of approximately 5 ETDRS letters in BCVA in patients with better baseline glycemic control, has important clinical implications. This result underscores the importance of optimizing systemic glycemic control as an adjunct to local anti-VEGF therapy in the management of DME. The observed difference suggests that achieving and maintaining target HbA1c levels can significantly enhance the visual benefits derived from anti-VEGF treatment. This is particularly relevant given that even small gains in visual acuity can have a substantial impact on patients' quality of life, daily functioning, and ability to perform tasks such as reading and driving. The relationship between glycemic control and visual acuity in DME is complex and multifactorial. Chronic hyperglycemia, the hallmark of diabetes, initiates a cascade of pathological events within the retinal microvasculature. These events include increased formation of advanced glycation end products (AGEs), activation of protein kinase C (PKC) isoforms, increased polyol pathway flux, and enhanced expression of inflammatory mediators. These biochemical changes contribute to the breakdown of the blood-retinal barrier, leading to increased vascular permeability, fluid leakage, and macular edema. Furthermore, chronic hyperglycemia can directly impair the function of retinal neurons and photoreceptors, contributing to visual dysfunction even in the absence of significant edema. Anti-VEGF agents, while highly effective in reducing vascular permeability and edema by neutralizing VEGF, do not directly address the underlying metabolic abnormalities caused by hyperglycemia. In patients with poorly controlled diabetes, the persistent hyperglycemic environment may counteract the beneficial effects of anti-VEGF therapy by sustaining or exacerbating the pathological processes that drive DME. This could explain why patients with higher HbA1c levels may exhibit a suboptimal response to anti-VEGF treatment or experience a less durable effect. In contrast, patients with better glycemic control may have a more favorable intraocular environment, characterized by reduced inflammation, oxidative stress, and vascular permeability. This milieu may allow anti-VEGF agents to exert their effects more efficiently, leading to greater and more sustained improvements in visual acuity. Moreover, improved glycemic control may also protect retinal neurons and photoreceptors from further damage, preserving their function and contributing to better visual outcomes. It is important to note that the observed association between HbA1c levels and visual acuity outcomes does not establish a causal relationship. While our findings strongly suggest that better glycemic control is associated with improved visual outcomes, other factors may also play a role. These factors include the duration of diabetes, the severity of diabetic retinopathy, the presence of other systemic comorbidities, and genetic predisposition. Further research, including well-designed prospective studies, is needed to confirm the causal nature of this association and to identify the specific mechanisms through which glycemic control influences visual outcomes in DME.[11-15]

In this meta-analysis, we observed a trend towards greater reduction in Central Retinal Thickness (CRT) in patients with better glycemic control, however, this difference did not reach statistical significance. This finding contrasts with the significant association observed for visual acuity outcomes and warrants careful consideration. Several potential explanations could account for this discrepancy. Firstly, anti-VEGF therapy is known to be highly effective in reducing CRT across a broad spectrum of patients, regardless of their glycemic status. The potent anti-permeability effects of these agents may lead to substantial anatomical improvement even in the presence of ongoing hyperglycemia. This could potentially mask more subtle differences in CRT reduction related to HbA1c levels. In essence, the "ceiling effect" of anti-VEGF therapy on CRT reduction might make it difficult to detect significant differences between the better and poorer glycemic control groups. Secondly, the assessment of CRT using Optical Coherence

Tomography (OCT) is subject to a degree of measurement variability. Different OCT devices, scanning protocols, and image analysis techniques can yield slightly different CRT measurements. This variability could introduce noise into the data and obscure subtle differences in CRT reduction between the HbA1c groups. Furthermore, CRT is a quantitative measure that reflects the physical thickness of the retina. While it provides valuable information about the extent of edema, it does not necessarily correlate perfectly with visual function. Visual acuity, on the other hand, is a functional measure that reflects the ability of the retina to resolve fine details. As discussed earlier, visual acuity is influenced not only by the presence of edema but also by the integrity and function of retinal neurons and photoreceptors. It is plausible that chronic hyperglycemia has a more pronounced effect on retinal function than on retinal thickness. Even if anti-VEGF therapy effectively reduces edema in both groups, the functional recovery of the retina may be impaired in patients with poorer glycemic control due to ongoing neuronal damage. This could explain why we observed a significant difference in visual acuity outcomes but not in CRT reduction. Thirdly, the heterogeneity observed in the meta-analysis of CRT reduction (I^2 = 75%) could have reduced the statistical power to detect a significant difference. Heterogeneity refers to the variability in results across different studies. In this case, the high degree of heterogeneity suggests that the effect of HbA1c on CRT reduction may vary considerably depending on the specific study population, methodology, and other factors. This variability makes it more difficult to draw a definitive conclusion about the overall effect of HbA1c on CRT reduction. Lastly, it is important to acknowledge that the follow-up duration in the included studies ranged from 12 to 36 months. It is possible that the impact of glycemic control on CRT reduction becomes more pronounced over longer periods. Studies with longer follow-up durations may be needed to fully elucidate the relationship between HbA1c levels and long-term anatomical outcomes in DME.[16-20]

4. Conclusion

This systematic review and meta-analysis of observational studies provides evidence that better baseline glycemic control, indicated by lower HbA1c levels (<7.5%), is significantly associated with improved long-term visual acuity outcomes in patients receiving anti-VEGF therapy for DME. The analysis demonstrated a clinically meaningful improvement of approximately 5 ETDRS letters in BCVA in patients with better baseline glycemic control. This finding underscores the importance of optimizing systemic glycemic control as an adjunct to local anti-VEGF therapy to maximize visual benefits in the treatment of DME. While a trend towards greater reduction in CRT was observed in patients with better glycemic control, this difference did not reach statistical significance. This discrepancy may be attributed to the potent effects of anti-VEGF agents on edema reduction, which could mask more subtle differences in CRT changes related to HbA1c levels, or to measurement variability in OCT assessments. Additionally, the high heterogeneity observed in the CRT reduction analysis suggests that the effect of HbA1c on anatomical outcomes may vary across studies. The findings of this meta-analysis highlight the importance of a comprehensive approach to DME management, integrating both local anti-VEGF treatment and systemic glycemic control. Optimizing HbA1c levels may enhance the effectiveness of anti-VEGF therapy in improving visual acuity, ultimately leading to better visual outcomes and quality of life for patients with DME.

5. References

1. Xu F, Liu S, Xiang Y, Hong J, Wang J, Shao Z, et al. Prediction of the short-term therapeutic effect of anti-VEGF therapy for diabetic macular edema using a generative adversarial network with OCT images. J Clin Med. 2022; 11(10): 2878.
2. Maatouk CM, Sastry R, Singh RP. Long term outcomes following anti-VEGF therapy for

diabetic macular edema. Expert Rev Ophthalmol. 2022; 17(5): 307–19.
3. Chen C, Wang Z, Yan W, Lan Y, Yan X, Li T, et al. Anti-VEGF combined with ocular corticosteroids therapy versus anti-VEGF monotherapy for diabetic macular edema focusing on drugs injection times and confounding factors of pseudophakic eyes: a systematic review and meta-analysis. Pharmacol Res. 2023; 196(106904): 106904.
4. Yu L, Hao X, Cheng J, Ling Y, Ren H, Mo B, et al. Predictive effect of TCED-HFV grading and imaging biomarkers on anti-VEGF therapy in diabetic macular edema. BMC Ophthalmol. 2023; 23(1): 232.
5. Hirano T, Kumazaki A, Tomihara R, Ito S, Hoshiyama K, Murata T. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Sci Rep. 2023; 13(1): 10901.
6. Del Cura Mar P, Carballés MJC, Sastre-Ibáñez M. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Indian J Ophthalmol. 2023; 71(8): 3091–4.
7. Nakao S, Kusuhara S, Murakami T. Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Arbeitsphysiologie. 2024; 262(12): 3749–59.
8. Dupas B, Castro-Farias D, Girmens J-F, Eginay A, Couturier A, Villeroy F, et al. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial. Trials. 2024; 25(1): 273.
9. Yang X, Cao Y, Cao X, Wang L, Zhang X, Zhang Z, et al. Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: a Bayesian network meta-analysis. Diabetes Obes Metab. 2025; 27(5): 2679–89.
10. Li G, Zhu N, Ji A. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2023; 102(50): e36370.
11. Santamaría J, Caminal JM, Cobos E, Biarnes M, Rodriguez-Leor R, Morwani R, et al. Correlation between topographic vessel density and retinal thickness changes in patients with diabetic macular edema treated with anti-VEGF therapy: Is it a suitable OCTA biomarker? J Pers Med. 2023; 13(12): 1718.
12. Kucukevcilioglu M, Yeşiltaş YS, Durukan AH, Unlu N, Onen M, Alp MN, et al. Real life multicenter comparison of 24-month outcomes of anti-VEGF therapy in diabetic macular edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-aflibercept switch. Medicina (Kaunas). 2023; 59(2): 263.
13. Subhi Y, Potapenko I, Hajari JN, la Cour M. Anti-VEGF treatment of diabetic macular edema in Denmark: Incidence, burden of therapy, and forecasting analyses. J Pers Med. 2023; 13(3).
14. Guha S, Sarkar S. Anti-VEGF therapy in a tertiary eye care centre for various ocular pathologies and outcomes for the treatment of diabetic macular edema (DME). Int J Fauna Biol Stud. 2024; 11(6): 20–3.
15. Saxena S, Singh M, Chaubey A, Mohan A, De S, Kaur A, et al. Anti-Vegf therapy leads to an improvement in grade of retinal pigment epithelium alterations on single layer retinal pigment epithelium map in diabetic macular

edema. Eur J Ophthalmol. 2023; 33(3): 1412–7.

16. Emami-Naeini P, Garmo V, Boucher N, Fernando R, Menezes A. Maintenance of vision needed to drive after intravitreal anti-VEGF therapy in patients with neovascular age-related macular degeneration and diabetic macular edema. Ophthalmol Retina. 2024; 8(4): 388–98.
17. Mehta H, Gabrielle P-H, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, et al. One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2024; 8(9): 872–9.
18. Fang Y-C, Lai IP, Lai T-T, Chen T-C, Yang C-H, Ho T-C, et al. Long-term change in renal function after intravitreal anti-VEGF treatment for diabetic macular edema: A 2-year retrospective cohort study. Ophthalmol Ther. 2023; 12(6): 2977–88.
19. Liu S, Hu W, Xu F, Chen W, Liu J, Yu X, et al. Prediction of OCT images of short-term response to anti-VEGF treatment for diabetic macular edema using different generative adversarial networks. Photodiagnosis Photodyn Ther. 2023; 41(103272): 103272.
20. Viggiano P, Vujosevic S, Palumbo F, Grassi MO, Boscia G, Borrelli E, et al. Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME. Photodiagnosis Photodyn Ther. 2024; 46(104042): 104042.